Drüeke T, Zins B, Naret C, Casadevall N, Goureau Y, Bererhi L, Peterlongo F, Castaigne J P, Zingraff J, Delons S
Hôpital Necker, Paris, France.
Adv Nephrol Necker Hosp. 1989;18:187-206.
Administration of recombinant erythropoietin constitutes a revolution in treatment of the anemia of chronic dialysis patients. Such treatment has been anxiously awaited. Its realization has been possible thanks to the spectacular progress allowed by the newly developed techniques of recombinant genetics. Correction of this type of anemia can be obtained rapidly and permanently if treatment is continued without interruption. It is followed by a remarkable transformation of the patient's physical and psychic status. The occurrence of certain side effects (e.g., elevation of blood pressure and an increased tendency toward vascular thrombosis), however, requires increased awareness in the follow-up of patients at risk and adaptation of erythropoietin administration to individual needs.
重组促红细胞生成素的应用是慢性透析患者贫血治疗领域的一次革命。这种治疗方法一直备受期待。由于重组遗传学新技术取得的显著进展，才得以实现这种治疗。如果持续不间断地进行治疗，这类贫血能够迅速且持久地得到纠正。随之而来的是患者身体和精神状态的显著改善。然而，某些副作用的出现（例如血压升高和血管血栓形成倾向增加），需要在对有风险的患者进行随访时提高警惕，并根据个体需求调整促红细胞生成素的给药方式。
